Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors

IMPORTANCE: Tamoxifen is commonly used as adjuvant therapy in breast cancer and is proposed to interfere with cytochrome P450 enzyme and P-glycoprotein pathways. Concurrent use with direct oral anticoagulants (DOACs) poses the threat of a potentially dangerous drug-drug interaction by leading to an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tzu-Fei, Clarke, Anna E., Awan, Arif A., Tanuseputro, Peter, Carrier, Marc, Sood, Manish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240900/
https://www.ncbi.nlm.nih.gov/pubmed/35763294
http://dx.doi.org/10.1001/jamanetworkopen.2022.19128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240900/
https://www.ncbi.nlm.nih.gov/pubmed/35763294
http://dx.doi.org/10.1001/jamanetworkopen.2022.19128

Ejemplares similares